Core Viewpoint - The company, Longshen Rongfa, announced that its subsidiary, Gansu Puan Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for two supplementary applications for clinical trials of the drug Brivaracetam oral film, which is intended for the treatment of schizophrenia [1] Group 1 - The approval includes the addition of two new specifications: 0.5mg and 1mg [1] - The supplementary application was accepted on May 20 and meets the requirements for drug registration [1] - The clinical trials for Brivaracetam oral film can continue as per the approved content [1]

Core Viewpoint - The company announced that its subsidiary, Puan Pharmaceutical, received approval from the National Medical Products Administration for two supplementary applications for clinical trials of the drug Brivaracetam oral film in 0.5mg and 1mg specifications, which are intended for the treatment of schizophrenia [1] Group 1 - The approval includes the addition of new specifications for the clinical trial of Brivaracetam oral film [1] - The clinical trial work will continue following the approval, as per the requirements of China's drug registration laws and regulations [1] - The drug must undergo clinical trials and receive further review and approval from the National Medical Products Administration before it can be produced and marketed [1]

证券代码：300534 证券简称：陇神戎发 公告编号：2025-051 甘肃陇神戎发药业股份有限公司 关于控股子公司获得药物临床试验补充申请批准通知书 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 甘肃陇神戎发药业股份有限公司（以下简称"公司"）控股子公司甘肃普安 制药股份有限公司（以下简称"普安制药"）于 2025 年 7 月 30 日收到国家药品 监督管理局核准签发的 2 份《药物临床试验补充申请批准通知书》，现将相关情 况公告如下： 一、《药物临床试验补充申请批准通知书》的主要内容 药物名称：布瑞哌唑口溶膜 受理号：CXHB2500137、CXHB2500138 通知书编号：2025LB00513、2025LB00514 根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 5 月 20 日受理的布瑞哌唑口溶膜为已获得批准的药物临床试验申请（受理号：C X H L 2 5 0 0 0 8 2，通知书编号 2025LP00911）的补充申请，此次药物临床试验补充 申请符合药品注册的有关要求，同意本品按照批准内容继续开展临床试验。批准 ...

Group 1: Company Overview and Key Products - Gansu Longshen Rongfa Pharmaceutical Co., Ltd. has two main products: Yuanhu Zhitong Diban and Xuanfei Zhike Heji, which are positioned as core offerings in the market [2][3] - Yuanhu Zhitong Diban is a unique product in China, included in the National Essential Medicines List, recognized for its effectiveness in treating various types of pain [2][3] - Xuanfei Zhike Heji is classified as a national-level new drug, suitable for cough relief, and has received multiple awards for its quality and effectiveness [3][4] Group 2: Product Development and Marketing Strategy - The company is focused on secondary development of major products and building technological barriers through various research projects [4][5] - Ongoing projects include clinical efficacy evaluations and production process improvements for Yuanhu Zhitong Diban and Xuanfei Zhike Heji [4][5] - A professional marketing platform is being developed to enhance brand influence and market share, targeting both hospitals and OTC markets [4][5] Group 3: Health Product Expansion - The company has launched several health products, including Huangqi Danggui capsules and plant-based beverages, with plans for further market promotion [5][6] - Future development will focus on health products that align with market demand, leveraging the parent company's advantages in the traditional Chinese medicine industry [5][6] Group 4: Industry Opportunities and Challenges - Recent government policies support the innovation and quality improvement of traditional Chinese medicine, creating a favorable environment for industry growth [6][7] - The aging population increases demand for chronic disease management and health maintenance, expanding market opportunities for traditional Chinese medicine products [6][7] - The company aims to enhance its competitive edge by improving product quality and increasing R&D investment in response to these opportunities [7]

证券代码：300534 证券简称：陇神戎发 公告编号：2025-050 甘肃陇神戎发药业股份有限公司 关于控股子公司取得换发后的《药品经营许可证》《医疗器 械经营许可证》及《第二类医疗器械经营备案凭证》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 甘肃陇神戎发药业股份有限公司（以下简称"公司"）控股子公司甘肃药业 集团三元医药有限公司（以下简称"三元医药"）因其《药品经营许可证》《医 疗器械经营许可证》及《第二类医疗器械经营备案凭证》的法定代表人信息变更 申请换证，于近日收到相关主管部门换发后的新证，现将有关情况公告如下： 一、换发后的《药品经营许可证》基本信息 企业名称：甘肃药业集团三元医药有限公司 统一社会信用代码：91620102MA73LG7052 经营地址：甘肃省兰州市城关区广武门街道秦安路 184 号第 6 层 601-603、 606、608、610 室 法定代表人（负责人）：张帆 有效期至：2028 年 9 月 18 日 许可证编号：甘 AA931100060 日常监督管理机构：甘肃省药品监督管理局 二、换发后的《医疗器械经营许可证》 ...

证券代码：300534 证券简称：陇神戎发 公告编号：2025-049 甘肃陇神戎发药业股份有限公司 关于控股子公司完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 甘肃陇神戎发药业股份有限公司控股子公司甘肃药业集团三元医药有限公 司（以下简称"三元医药"）因经营工作需要，于 2025 年 6 月 18 日完成了法定 代表人、董事、监事等信息的工商变更登记手续，并取得了兰州市城关区市场监 督管理局核准换发的《营业执照》。 3.类型：有限责任公司（自然人投资或控股） 4.住所：甘肃省兰州市城关区广武门街道秦安路 184 号第 6 层 601-603、 606、608、610 室 5.法定代表人：张帆 6.注册资本：壹仟万元整 7.成立日期：2018 年 7 月 18 日 8.经营范围：许可项目：药品批发；药品进出口；第三类医疗器械经营；药 品零售；消毒器械销售；中药饮片代煎服务；食品销售（依法须经批准的项目， 经相关部门批准后方可开展经营活动） 一般项目：第一类医疗器械销售；第二类医疗器械销售；保健食品（预包装） 销售；医护人 ...

证券代码：300534 证券简称：陇神戎发 公告编号：2025-048 甘肃陇神戎发药业股份有限公司 2025年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会未出现否决议案的情形； 4.会议召集人：公司董事会 5.会议主持人：董事长康永红先生 6.本次股东会的召集、召开以及表决程序符合《公司法》等法律、行政法规、 部门规章、规范性文件和《公司章程》的规定。 2.本次股东会不涉及变更以往股东会已通过的决议的情形。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间： （1）现场会议召开时间：2025 年 6 月 17 日下午 14:00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025年6月17日9:15—9:25，9:30—11:30和13:00—15:00；通过深圳证券交易所 互联网投票系统进行网络投票的时间为2025年6月17日9:15—15:00期间的任意 时间。 2.现场会议地点：甘肃省兰州市榆中县定远镇国防路 10 号公司六楼会议室 3.会议召开方式：本次股东 ...

北京德恒（兰州）律师事务所 关于甘肃陇神戎发药业股份有限公司 2025 年第三次临时股东会 之 法律意见书 甘肃省兰州市城关区雁园路 601 号甘肃省商会大厦 A 座 15 层 邮编：730030 电话：（0931）8260111 传真：（0931）8456612 法律意见书 致：甘肃陇神戎发药业股份有限公司 北京德恒（兰州）律师事务所（以下简称"本所"）受甘肃陇神戎发药业股 份有限公司（以下简称"陇神戎发""贵公司""公司"）委托，指派范文泽、 张昕律师（以下简称"本所律师"）出席贵公司 2025 年第三次临时股东会（以 下简称"本次股东会"），并对本次股东会的合法性出具法律意见书。 关于甘肃陇神戎发药业股份有限公司 2025 年第三次临时股东会法律意见书 北京德恒（兰州）律师事务所 关于甘肃陇神戎发药业股份有限公司 2025 年第三次临时股东会之 本所律师列席了贵公司本次股东会，并根据本法律意见书出具日前已发生或 存在的事实和《中华人民共和国公司法》（以下简称《公司法》）、《中华人民 共和国证券法》（以下简称《证券法》）、《上市公司股东会规则》以及《甘肃 陇神戎发药业股份有限公司章程》（以下简称《公司章程 ...

Meeting Details - The meeting was held on June 17, 2025, at 14:00, with online voting available from 9:15 to 15:00 on the same day [1] - A total of 192 shareholders attended the meeting, representing 118,310,230 shares, which is 39.0019% of the company's total share capital [1][2] - Among the attendees, 4 were present at the venue, while 188 participated through proxy voting, representing 4,250,920 shares or 1.4070% of the voting shares [1] Voting Results - The meeting combined on-site and online voting for the proposals, with 118,203,930 shares voting in favor, accounting for 99.9958% of the voting shares [3] - Small shareholders voted with 4,161,720 shares in favor, representing 97.5094% of the small shareholders' voting shares [3][4] - The proposals were classified as special resolutions and received the necessary majority for approval [3][4] Legal Opinion - The legal representatives from Beijing Deheng (Lanzhou) Law Firm confirmed that the meeting's procedures complied with legal and regulatory requirements, and the resolutions passed were valid [10][11]

Core Viewpoint - Several listed companies in the Shanghai and Shenzhen markets announced significant updates, including changes in control, regulatory measures, and sales performance, which may present investment opportunities and risks for investors [2]. Company Announcements - Zhongying Electronics announced that its controlling shareholder is planning a change in control, leading to a suspension of trading from June 9, 2025, for up to two trading days [3]. - ST Lutong received an administrative regulatory measure from the Jiangsu Securities Regulatory Bureau due to internal control deficiencies and failure to disclose significant lawsuits and account freezes [4]. - Lianhua Technology clarified that it does not directly produce chlorantraniliprole and that the related matters have limited impact on its overall business [5]. - Longshen Rongfa's subsidiary received a CNAS laboratory accreditation certificate, which is expected to positively influence future operations, though it will not significantly impact current performance [6]. Sales Performance - Yisheng Co. reported a significant increase in May sales of breeding pigs, with a total of 10,849 heads sold, representing a year-on-year increase of 207.08% [7]. Shareholding Changes - Shentong Technology's shareholder, Biheng Investment, plans to reduce its stake by up to 3%, equating to a maximum of 12.88 million shares [8]. - Ruoyuchen's shareholder, Langzi Co., intends to reduce its stake by up to 3%, not exceeding 4.7681 million shares [9]. - Oujing Technology's shareholder, Wanzhao Huigu, plans to reduce its stake by up to 3%, equating to a maximum of 5.7722 million shares [10]. - Jindan Technology's shareholder, Guangzhou Chengxin, plans to reduce its stake by up to 2.93%, equating to a maximum of 5.635 million shares [11]. - Huashu Gaoke's shareholder, Guotou Chuangye Fund, plans to reduce its stake by up to 2.2%, equating to a maximum of 9.1117 million shares [12]. - Zhongke Soft's shareholder, Kesuan Chuangyuan, plans to reduce its stake by up to 2%, equating to a maximum of 16.6208 million shares [13]. - Hengrun Co. announced multiple shareholders planning to reduce their stakes, with total reductions not exceeding 1.89% of the company's shares [14]. - Del Shares' shareholder, Wuxu 15 Fund, plans to reduce its stake by up to 1.987%, equating to a maximum of 3 million shares [15]. - Jian Ke Yuan's shareholder, Jian Ke Investment, plans to reduce its stake by up to 1% [17]. - Mindong Electric's shareholder, Fujian Investment Development Group, plans to reduce its stake by up to 1% [18]. - Puli Software's chairman and executives plan to reduce their stakes by a total of up to 0.69% [19].